Andrzej J. Jakubowiak

Oncology

5841 S Maryland Ave
Chicago, IL 60637

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 146 publications

Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma.

Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma.

Journal: JCO precision oncology

Published: July 23, 2026

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Journal: Science translational medicine

Published: May 27, 2026

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 14, 2026

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 14, 2026

Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE.

Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE.

Journal: Blood advances

Published: December 05, 2025

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

Journal: Blood advances

Published: December 05, 2025

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Journal: The Lancet. Haematology

Published: November 21, 2025

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Journal: Advances in therapy

Published: September 02, 2025

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Journal: Nature genetics

Published: June 09, 2025

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 03, 2025

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.

Journal: HemaSphere

Published: March 21, 2025

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.

Journal: Blood neoplasia

Published: March 17, 2025

Showing 1-12 of 146

Last Updated: 09/26/2026